NASDAQ:KMPH - Nasdaq - US4884452065 - Common Stock - Currency: USD
NASDAQ:KMPH (2/28/2023, 8:00:03 PM)
5.81
-0.02 (-0.34%)
The current stock price of KMPH is 5.81 USD. In the past month the price increased by 7.79%. In the past year, price increased by 10.46%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 24 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The firm also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.
KEMPHARM INC
1180 Celebration Blvd Ste 103
Celebration FLORIDA 34747 US
CEO: Travis C. Mickle
Employees: 24
Company Website: http://www.kempharm.com/
Phone: 13219393416.0
The current stock price of KMPH is 5.81 USD. The price decreased by -0.34% in the last trading session.
The exchange symbol of KEMPHARM INC is KMPH and it is listed on the Nasdaq exchange.
KMPH stock is listed on the Nasdaq exchange.
9 analysts have analysed KMPH and the average price target is 22.78 USD. This implies a price increase of 292.08% is expected in the next year compared to the current price of 5.81. Check the KEMPHARM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KEMPHARM INC (KMPH) has a market capitalization of 200.47M USD. This makes KMPH a Micro Cap stock.
KEMPHARM INC (KMPH) currently has 24 employees.
KEMPHARM INC (KMPH) has a support level at 5.43 and a resistance level at 5.87. Check the full technical report for a detailed analysis of KMPH support and resistance levels.
The Revenue of KEMPHARM INC (KMPH) is expected to decline by -59.96% in the next year. Check the estimates tab for more information on the KMPH EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KMPH does not pay a dividend.
KEMPHARM INC (KMPH) will report earnings on 2023-03-28, before the market open.
KEMPHARM INC (KMPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
ChartMill assigns a technical rating of 7 / 10 to KMPH. When comparing the yearly performance of all stocks, KMPH is one of the better performing stocks in the market, outperforming 90.81% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to KMPH. While KMPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months KMPH reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 64.83% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0.14 |
ChartMill assigns a Buy % Consensus number of 84% to KMPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -143.91% and a revenue growth -59.96% for KMPH